Vertex Pharmaceuticals Inc released corrected data involving its cystic fibrosis treatments on Tuesday that lowered the number of patients who showed certain levels of improved lung function, sending its ...
Vertex (VRTX) reported interim data on a Phase II study targeting Cystic Fibrosis, which affects 30,000 in the United States and 70,000 worldwide. Previously, the company's KALYDECO drug - which won FDA approval in January - could only be used to treat about 4% of those patients.
Robert Weinstein submits:
The Way means inducing the people to have the same aim as the leadership, so that they will share death and share life, without fear of danger. -- Sun Tsu, The Art of War.
Vertex Pharmaceuticals Incorporated (VRTX) of Cambridge, MA was up strongly today to close at $49.95 a share.
By Ry Frank:Vertex Pharmaceuticals (VRTX) shares recently dropped 20% on the news that its VX-809/Kalydeco Cystic Fibrosis combination therapy data had been inflated. Instead of 46% of the patients in the Phase II studies showing an improvement in lung function of 5% or more, the actual figure was 35%.